Triple Negative Breast Cancer (TNBC)

SEP 8, 2026 · PHASE 1 TRIAL

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

ClinicalTrials.gov

This is a first-in-human Phase 1b study registration with no results posted; it describes planned enrollment and primary endpoints only, representing early-stage clinical evaluation.

AUG 13, 2026 · PHASE 1/2 TRIAL

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

ClinicalTrials.gov

This is a Phase 1/2 registry record for a planned study with no reported results; enrollment is estimated at only 10 participants across a safety lead-in and randomized cohort, making it an early-stage feasibility and safety assessment.

AUG 12, 2026 · PHASE 3 TRIAL

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC

ClinicalTrials.gov

This is a clinical trial registry record for a planned Phase 3 study with no results posted; recruitment has not yet begun.

AUG 10, 2026 · PHASE 1 TRIAL

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

ClinicalTrials.gov

First-in-human Phase 1 trial of a novel proteasome inhibitor designed to evaluate safety, tolerability, and preliminary anti-tumor activity; no results are yet reported in this registry record.

AUG 7, 2026 · PHASE 2 TRIAL

Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

ClinicalTrials.gov

Phase 2 interventional trial in planning stage with no posted results; early-phase design studying a novel immunotherapy combination in TNBC.